BioLife Solutions, Inc.

BLFSNASDAQHealthcare● Active

$26.58

$-0.07(-0.26%)

Market Cap$1.3B

P/E Ratio—

52W High$29.62

52W Low$17.86

Avg Volume511K

Open$26.78

Beta1.97

Free Cash Flow Financials Revenue

BioLife Solutions, Inc. (BLFS) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

BLFS · free cash flow · updated Jun 8, 2026

Core FCF metrics

BLFS · FCF · TTM · margin & CAGR

Free cash flow was $10.6M for FY2025 (fiscal year ending 2025-12-31), up 104.4% year-over-year The FCF margin was 11.1%. Five-year CAGR stands at +41.4%.

FY2025 Free Cash Flow$10.6M▲ +104.4% YoY

Trailing 12M (TTM)−$1.8MTrailing 4Q sum · TTM negative vs latest FY positive

FCF Margin11.1%$10.6M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGR+41.4%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

BLFS · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$20.1M(9M)$10.6M▲ +104.4%11.1%

FY2024$8.4M(3M)$5.2M▲ +127.6%6.3%

FY2023−$12.5M(6M)−$18.9M▲ +0.0%-24.9%

FY2022−$8.5M(10M)−$18.9M▼ 42.8%-24.8%

FY2021−$4.8M(8M)−$13.2M▼ 802.5%-11.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

BLFS · P/FCF · FCF yield · FCF per share

BioLife Solutions, Inc. (BLFS) valuation ratios are currently unavailable — market cap, share count, or TTM data could not be retrieved from our data provider.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

Valuation ratios are unavailable — market cap, share count, or TTM data could not be retrieved. Individual metrics are shown where available.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

BLFS · cash flow statement · operating / investing / financing

For FY2025, BioLife Solutions, Inc. generated $20.1M in operating cash flow and spent 9M in capital expenditures, yielding $10.6M in free cash flow.

Operating Activities

+$20.1M

Cash from core business operations

2025-12-31

Investing Activities

−$71.5M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$10.9M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($20.1M) − |CapEx| (9M) = FCF ($10.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

BLFS vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

BioLife Solutions, Inc.YOU

BLFS

$10.6M+104.4%11.1%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

BioLife Solutions, Inc. (BLFS) reported free cash flow of $10.6M for FY2025 (fiscal year ending 2025-12-31), up 104.4% year-over-year. The FCF margin was 11.1%.

Based on available data, BioLife Solutions, Inc. has maintained positive free cash flow for at least 6 fiscal year(s). FCF peaked at $10.6M in FY2025. The 5-year CAGR stands at +41.4%.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

BLFS free cash flow · 8 questions

BioLife Solutions, Inc. free cash flow was $10.6M for FY2025, up 104.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$1.8M.

BLFS free cash flowBLFS FCFBLFS FCF 2025BLFS free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · BioLife Solutions, Inc. · BioLife Solutions, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026